What are the indications for Invega (paliperidone)?

Invega (Paliperidone) Indications

Invega (paliperidone extended-release) is FDA-approved for two primary indications: treatment of schizophrenia in adults and adolescents (ages 12-17 years), and treatment of schizoaffective disorder in adults as monotherapy or adjunctive therapy with mood stabilizers and/or antidepressants. 1

FDA-Approved Indications

Schizophrenia

• Adults: Paliperidone ER is indicated for acute and maintenance treatment of schizophrenia, with efficacy established in three 6-week acute trials and one maintenance trial demonstrating effectiveness in delaying time to relapse 1
• Adolescents (12-17 years): Approved for schizophrenia treatment based on one 6-week efficacy trial in this age group 1

Schizoaffective Disorder

• Adults only: Indicated for treatment of schizoaffective disorder either as monotherapy or as adjunctive therapy combined with mood stabilizers and/or antidepressants 1
• Efficacy was established in two 6-week trials in adult patients with schizoaffective disorder 1, 2

Dosing Framework by Indication

Schizophrenia - Adults

• Recommended starting dose: 6 mg once daily (no initial titration required) 1
• Dose range: 3-12 mg/day, with maximum dose of 12 mg/day 1
• Dose increases above 6 mg should occur only after clinical reassessment, at intervals exceeding 5 days, in 3 mg increments 1

Schizophrenia - Adolescents

• Starting dose: 3 mg once daily (no initial titration required) 1
• Weight-based maximum dosing: 6 mg/day for patients <51 kg; 12 mg/day for patients ≥51 kg 1
• Dose increases should occur at 3 mg increments with intervals exceeding 5 days 1

Schizoaffective Disorder - Adults

• Recommended starting dose: 6 mg once daily (no initial titration required) 1
• Dose range: 3-12 mg once daily, with maximum dose of 12 mg/day 1
• Dose adjustments should occur at intervals exceeding 4 days in 3 mg increments 1

Critical Safety Considerations

Boxed Warning

• Paliperidone carries an FDA boxed warning for increased mortality in elderly patients with dementia-related psychosis - this is NOT an approved indication 1

Key Monitoring Parameters

• QT prolongation risk: avoid use with other QT-prolonging drugs and in patients with risk factors for prolonged QT interval 1
• Metabolic changes: monitor for hyperglycemia, dyslipidemia, and weight gain throughout treatment 1
• Hyperprolactinemia: prolactin elevations occur and persist during chronic administration 1
• Extrapyramidal symptoms and tardive dyskinesia: monitor for movement disorders and discontinue if clinically appropriate 1
• Neuroleptic malignant syndrome: requires immediate discontinuation and close monitoring if suspected 1

Pharmacokinetic Advantages

• Paliperidone undergoes limited hepatic metabolism (unlike its parent drug risperidone), minimizing risks of hepatic drug-drug and drug-disease interactions 3, 4
• The extended-release formulation provides stable plasma concentrations over 24 hours with peak levels at approximately 24 hours post-dose 3
• Renal excretion is the major route of elimination, making it potentially preferable when liver disease or drug interactions complicate risperidone dosing 3

Off-Label Considerations from Guidelines

• While paliperidone was mentioned in guidelines for augmentation therapy in treatment-resistant depression, this remains an off-label use without FDA approval for mood disorders as monotherapy 5
• Antipsychotic polypharmacy including paliperidone has been studied in schizophrenia management, though monotherapy remains the standard recommendation 6